Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group
暂无分享,去创建一个
I. Boukovinas | N. Ziras | V. Georgoulias | S. Agelaki | D. Mavroudis | E. Saloustros | G. Rigas | I. Varthalitis | S. Kakolyris | K. Kalbakis | G. Fountzilas | C. Christophylakis | N. Kentepozidis | P. Papakotoulas | D. Hatzidaki | Georgios Rigas
[1] M. Thill,et al. [The 20-year results of 5‑year hormone therapy in breast cancer : Early Breast Cancer Trialists' Collaborative Group (EBCTCG)]. , 2018, Der Internist.
[2] H. Gómez,et al. Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] V. Georgoulias,et al. Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] L. V. van't Veer,et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. , 2016, The New England journal of medicine.
[5] M. Buyse,et al. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] I. Boukovinas,et al. Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG) , 2014, Breast Cancer Research and Treatment.
[7] S. Paik,et al. Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] R. Gelber,et al. Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] Yuanyuan Zhang,et al. Sequential versus concurrent anthracyclines and taxanes as adjuvant chemotherapy of early breast cancer: a meta-analysis of phase III randomized control trials. , 2012, Breast.
[10] D. Cutter,et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials , 2012, The Lancet.
[11] Jong-Hyeon Jeong,et al. Breast cancer adjuvant therapy: time to consider its time-dependent effects. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] E. Perez,et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. , 2010, The New England journal of medicine.
[13] Y Wang,et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[14] M. Krzakowski,et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] A. Glas,et al. Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer , 2016 .
[16] D. Mavroudis,et al. Paclitaxel and docetaxel in the treatment of breast cancer. , 2008, Expert opinion on pharmacotherapy.